LKB1‐SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition
Sarah Proteau(Inserm), Thomas Strub(Inserm), Thibault Barouillet(Inserm), Christophe Vandier(Université de Tours), Federica Sella(University of Zurich), Nathalie M. Mazure(Inserm), Céline Pisibon(Inserm), Karine Bille(Inserm), Patrick Brest(Centre National de la Recherche Scientifique), Mitchell P. Levesque(Duke University), Olivier Mignen(Inserm), Nicole Arrighi(Inserm), Lauris Gastaud(Leiden University Medical Center), Laurent Yvan‐Charvet(Inserm), Corine Bertolotto(Centre Méditerranéen de Médecine Moléculaire), Frédéric Bost(Inserm), Emily Bernstein(Icahn School of Medicine at Mount Sinai), Robert Ballotti(Inserm), Sandra Lassalle(Université Côte d'Azur), Imène Krossa(Université Côte d'Azur), Chrystel Husser(Inserm), Saul Carcamo(Icahn School of Medicine at Mount Sinai), Yann Chéli(Inserm), Sacha Nahon‐Estève(Université Côte d'Azur), Mélanie Dalmasso(Inserm), Arnaud Martel(Université de Sherbrooke), Solange Landreville(Université Laval), Maxime Guéguinou(Université de Tours), Marie Irondelle(Inserm), Stéphanie Baillif(Université Côte d'Azur), Dan Hasson(Icahn School of Medicine at Mount Sinai), Simon Turcotte(Centre Hospitalier de l’Université de Montréal)
Cited by 16
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Cholesterol Efflux and Atheroprotection
|Circulation|2012|949
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
|Oncogene|2008|852
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
|Nature|2013|735
Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1
|Cancer Research|2011|620